Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.isci.2021.102898 http://scihub22266oqcxt.onion/10.1016/j.isci.2021.102898 34316549!8297982!34316549     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34316549&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       iScience 2021 ; 24 (8): 102898 Nephropedia Template TP {{tp|p=34316549|t=2021. Effect of time and titer in convalescent plasma therapy for COVID-19 |pdf=|usr=}}{{34316549}} gab.com Text Effect of time and titer in convalescent plasma therapy for COVID-19 JO: iScience http://www.kidney.de/pget.php?&tw=1&pmid=34316549 #FOAvip The clinical benefit of convalescent plasma (CP) for patients with coronavirus disease (COVID)-19 is still debated. In this systematic review and meta-analysis, we selected 10 randomized clinical trials (RCTs) and 15 non-randomized studies (total number of patients = 22,591) of CP treatment and evaluated two different scenarios: (1) disease stage of plasma recipients and (2) donated plasma antibody titer, considering all-cause mortality at the latest follow-up. Our results show that, when provided at early stages of the disease, CP significantly reduced mortality: risk ratio (RR) 0.72 (0.68, 0.77), p < 0.00001, while provided in severe or critical conditions, it did not (RR: 0.94 [0.86, 1.04], p = 0.22). On the other hand, the benefit on mortality was not increased by using plasma with a high-antibody titer compared with unselected plasma. This meta-analysis might promote CP usage in patients with early-stage COVID-19 in further RCTs to maximize its benefit in decreasing mortality, especially in less affluent countries. Twit Text FOAVip Effect of time and titer in convalescent plasma therapy for COVID-19 ????iScience http://www.kidney.de/pget.php?&tw=1&pmid=34316549 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34316549 #FOAvip English Wikipedia <ref>{{Cite pmid|34316549}}</ref> Effect of time and titer in convalescent plasma therapy for COVID-19 #MMPMID34316549 de Candia P; Prattichizzo F; Garavelli S; La Grotta R; De Rosa A; Pontarelli A; Parrella R; Ceriello A; Matarese G iScience 2021[Aug]; 24 (8): 102898 PMID34316549show ga The clinical benefit of convalescent plasma (CP) for patients with coronavirus disease (COVID)-19 is still debated. In this systematic review and meta-analysis, we selected 10 randomized clinical trials (RCTs) and 15 non-randomized studies (total number of patients = 22,591) of CP treatment and evaluated two different scenarios: (1) disease stage of plasma recipients and (2) donated plasma antibody titer, considering all-cause mortality at the latest follow-up. Our results show that, when provided at early stages of the disease, CP significantly reduced mortality: risk ratio (RR) 0.72 (0.68, 0.77), p < 0.00001, while provided in severe or critical conditions, it did not (RR: 0.94 [0.86, 1.04], p = 0.22). On the other hand, the benefit on mortality was not increased by using plasma with a high-antibody titer compared with unselected plasma. This meta-analysis might promote CP usage in patients with early-stage COVID-19 in further RCTs to maximize its benefit in decreasing mortality, especially in less affluent countries. ?Effect of time and titer in convalescent plasma therapy for COVID-19 (epmc).pdf DeepDyve Pubget Overpricing